Accounting for assay performance when estimating the temporal dynamics in SARS-CoV-2 seroprevalence in the U.S.
Garcia-Carreras, B.; Hitchings, M. D.; Johansson, M. A.; Biggerstaff, M.; Slayton, R. B.; Healy, J. M.; Lessler, J.; Quandelacy, T.; Salje, H.; Huang, A. T.; Cummings, D. A.
Show abstract
Estimating the incidence of SARS-CoV-2 infection is central to understanding the state of the pandemic. Seroprevalence studies are often used to assess cumulative infections as they can identify asymptomatic infection. Since July 2020, commercial laboratories have conducted nationwide serosurveys for the U.S. CDC. They employed three assays, with different sensitivities and specificities, potentially introducing biases in seroprevalence estimates. Using mechanistic models, we show that accounting for assays explains some of the observed state-to-state variation in seroprevalence, and when integrating case and death surveillance data, we show that when using the Abbott assay, estimates of proportions infected can differ substantially from seroprevalence estimates. We also found that states with higher proportions infected (before or after vaccination) had lower vaccination coverages, a pattern corroborated using a separate dataset. Finally, to understand vaccination rates relative to the increase in cases, we estimated the proportions of the population that received a vaccine prior to infection.
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Estimation and worldwide monitoring of the effective reproductive number of SARS-CoV-2 93%
- SARS-CoV-2 transmission dynamics in South Africa and epidemiological characteristics of the Omicron variant 93%
- Changes in transmission of Enterovirus D68 (EV-D68) in England inferred from seroprevalence data 93%
Similar papers in this journal
Similar papers in this journal
- Incident COVID-19 infections before Omicron in the U.S 94%
- Evaluating primary and booster vaccination prioritization strategies for COVID-19 by age and high-contact employment status using data from contact surveys 93%
- Quantifying individual-level heterogeneity in infectiousness and susceptibility through household studies 93%
Similar papers in this journal
- Characterizing the spatiotemporal heterogeneity of the COVID-19 vaccination landscape 94%
- Waning of two-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection is robust to depletion-of-susceptibles bias 93%
- Comparative evaluation of methodologies for estimating the effectiveness of non-pharmaceutical interventions in the context of COVID-19: a simulation study 92%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.